Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

The cost effectiveness of docetaxel and active symptom control versus active symptom control alone for refractory oesophagogastric adenocarcinoma : economic analysis of the COUGAR-02 trial

Tools
- Tools
+ Tools

Meads, David M., Marshall, A. (Andrea)‏, Hulme, Claire T., Dunn, Janet A. and Ford, Hugo E. R. (2016) The cost effectiveness of docetaxel and active symptom control versus active symptom control alone for refractory oesophagogastric adenocarcinoma : economic analysis of the COUGAR-02 trial. PharmacoEconomics, 34 (1). pp. 33-42. doi:10.1007/s40273-015-0324-5

[img] PDF
WRAP_Meads - COUGAR II_HE_PharmacoEcon.pdf - Accepted Version - Requires a PDF viewer.

Download (740Kb)
Official URL: http://dx.doi.org/10.1007/s40273-015-0324-5

Request Changes to record.

Abstract

Background

The COUGAR-02 trial recently showed survival and quality-of-life benefits of docetaxel and active symptom control (DXL + ASC) over active symptom control (ASC) alone in patients with refractory oesophagogastric adenocarcinoma.

Aim

The aim of this study was to conduct an economic evaluation conforming to National Institute for Health and Care Excellence (NICE) technology appraisal guidance to evaluate the cost effectiveness of DXL + ASC versus ASC from the perspective of the English National Health Service (NHS).

Methods

Cost-utility analyses were conducted using trial data. Utility values were captured using the EQ-5D completed by patients at 3- and 6-weekly intervals, while resource use was captured using nurse-completed report forms and patient reports. Incremental cost-effectiveness ratios (ICERs) were calculated and the main outcome was cost per incremental quality-adjusted life-year (QALY). Nonparametric bootstrapping was conducted to capture sampling uncertainty and to generate a cost-effectiveness acceptability curve (CEAC). The analysis horizon was the trial period (median follow-up 12 months) and no modelling or discounting of future costs and benefits was conducted.

Results

Average costs were £9352 and £6218 for DXL + ASC and ASC, respectively, and average QALYs were 0.302 and 0.186, respectively. This yielded an ICER of £27,180 for DXL + ASC. DXL + ASC had a 24 % chance of being cost effective at a £20,000 QALY threshold (lambda) and a mean net monetary benefit of −£821; this rose to 59 % and £332 when the threshold was raised to £30,000. If NICE end-of-life criteria are applied, the probability of cost effectiveness increases to 90 % (at lambda = £50,000). Results were robust to sensitivity analyses.

Conclusions

DXL + ASC is likely to be cost effective if an end-of-life premium is applied. Further research should determine the impact of different utility measurement strategies and different chemotherapy delivery modes on estimates of cost effectiveness.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Adenocarcinoma -- Treatment -- Cost effectiveness, Esophagus -- Cancer -- Treatment -- Cost effectiveness, Stomach -- Cancer -- Treatment -- Cost effectiveness, Docetaxel, Chemotherapy
Journal or Publication Title: PharmacoEconomics
Publisher: Adis International Ltd.
ISSN: 1170-7690
Official Date: January 2016
Dates:
DateEvent
January 2016Published
4 September 2016Available
Volume: 34
Number: 1
Page Range: pp. 33-42
DOI: 10.1007/s40273-015-0324-5
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: Cancer Research UK (CRUK), NIHR Cambridge Biomedical Research Centre
Grant number: Grant number C21276/A12372

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us